


References: 1. Antozzi C, et al. Lancet Neurol. 2025;24(2):105–16; 2. Antozzi C, et al. Neurology. 2024;102(2):e207937; 3. Seth NP, et al. mABS. 2025;17(1):2461191; 4. Ling LE, et al. Clin Pharmacol Ther. 2019;105(4):1031–9; 5. Pérez-Ruixó JJ, et al. Presented at the AAN Annual Meeting; 22–27 April 2023; Boston, MA, USA; 6. IMAAVY® (nipocalimab). Prescribing Information. Ministry of Health (Israel)
gMG: general myasthenia gravis; MG-ADL: Myasthenia Gravis Activities of Daily Living; MuSK: muscle-specific kinase; QMG: Quantitative Myasthenia Gravis score; AChR: Acetylcholine Receptor
The data in this page is based on published clinical studies, please refer to the full references provided within this page For further information regarding IMAAVY® (Nipocalimab), including full indication wording, all adverse effects and data registered in Israel, please refer to the prescribing information on the Israeli: https://israeldrugs.health.gov.il/#!/byDrug


